Alexandre Tavartkiladze
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alexandre Tavartkiladze has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Russel Joseph Reiter
Department of Cell Systems and Anatomy, UT Health San Antonio, Long School of Medicine, San Antonio, TX 78229, USA
11 shared publications - Pati Revazishvili
Department of Internal Medicine, Faculty of Medicine, Tbilisi State Medical University, 0186 Tbilisi, Georgia
10 shared publications - Levan Tavartkiladze
Institute for Personalized Medicine, 0186 Tbilisi, Georgia
9 shared publications - Dinara Kasradze
Institute for Personalized Medicine, 0186 Tbilisi, Georgia
7 shared publications - Nana Okrostsvaridze
Institute for Personalized Medicine, 0186 Tbilisi, Georgia
7 shared publications - Michel Burnier
University of Lausanne
6 shared publications
Latest Publications
- Open Access
- 7 October 2026
- Published by Taylor & Francis in Annals of Medicine
- Vol. 58 (1)
Lower 24-hour urinary 6-sulfatoxymelatonin and exploratory bile-acid and microbiome associations in adults with dyslipidemia: a prospectively enrolled cross-sectional study
Melatonin (N-acetyl-5-methoxytryptamine) is traditionally described as the hormone of darkness because of its nocturnal pineal secretion and central role in circadian organization. It also acts as ...
- 7 October 2026
- Published by Taylor & Francis in Annals of Medicine
- Vol. 58 (1)
Open AccessLower 24-hour urinary 6-sulfatoxymelatonin and exploratory bile-acid and microbiome associations in adults with dyslipidemia: a prospectively enrolled cross-sectional study
Melatonin (N-acetyl-5-methoxytryptamine) is traditionally described as the hormone of darkness because of its nocturnal pineal secretion and central role in circadian organization. It also acts as ...
- Open Access
Relative Melatonergic Status and Systemic Inflammatory, Oxidative, and Biological Aging Burden in Adults: An Exploratory Cross-Sectional Biomarker Analysis
Background/objectives: Melatonin has circadian, antioxidant, mitochondrial, and immunomodulatory functions, but human data linking relative melatonergic status to coordinated systemic biomarker burden remain limited. We examined this association and tested its internal robustness to alternative score construction, outlier handling, and missing-data assumptions. Methods: We performed an adult-only cross-sectional secondary analysis of a deidentified biomarker dataset. Of 322 source records, six participants younger than 18 years and two records without age were excluded, yielding 314 adults. Plasma melatonin and 24 h urinary aMT6s were converted to within-cohort rank percentiles and averaged to form a relative melatonergic-axis score. Equal-weight z-score composites represented inflammation, oxidative damage, antioxidant deficit, and biological aging/biological injury; their mean was the integrated systemic biomarker-burden score. Analyses included Kruskal–Wallis tests; Spearman correlations with bootstrap confidence intervals; standardized regression adjusted for age, sex, and BMI; robust covariance estimates; principal component analysis (PCA), winsorization, leave-one-domain/marker-out analyses, and missing-BMI sensitivity models. Results: The lower, intermediate, and higher relative melatonergic tertiles included 105, 104, and 105 adults, respectively. The melatonergic-axis score correlated inversely with integrated systemic burden (Spearman ρ = −0.944; 5000-resample bootstrap 95% CI, −0.953 to −0.931; p < 0.001). In age-, sex-, and BMI-adjusted complete-case models (N = 250), each 1 SD higher axis score was associated with a 0.95 SD lower integrated burden (β = −0.949; HC3 95% CI, −0.983 to −0.915; p < 0.001). Results were similar for separate plasma melatonin and aMT6s models, winsorized composites, a PCA-derived score (PC1 explained 75.5% of marker variance; ρ = −0.947), leave-one-domain/marker-out analyses, and missing-BMI sensitivity models. Conclusions: Lower relative melatonergic status was associated with a highly coordinated adverse systemic biomarker pattern. The exceptional magnitude of the association requires audit of primary assay provenance and independent external replication. Because cancer, microbiome, and liquid biopsy endpoints were not measured, oncology implications remain untested prospective hypotheses.
Open AccessRelative Melatonergic Status and Systemic Inflammatory, Oxidative, and Biological Aging Burden in Adults: An Exploratory Cross-Sectional Biomarker Analysis
Background/objectives: Melatonin has circadian, antioxidant, mitochondrial, and immunomodulatory functions, but human data linking relative melatonergic status to coordinated systemic biomarker burden remain limited. We examined this association and tested its internal robustness to alternative score construction, outlier handling, and missing-data assumptions. Methods: We performed an adult-only cross-sectional secondary analysis of a deidentified biomarker dataset. Of 322 source records, six participants younger than 18 years and two records without age were excluded, yielding 314 adults. Plasma melatonin and 24 h urinary aMT6s were converted to within-cohort rank percentiles and averaged to form a relative melatonergic-axis score. Equal-weight z-score composites represented inflammation, oxidative damage, antioxidant deficit, and biological aging/biological injury; their mean was the integrated systemic biomarker-burden score. Analyses included Kruskal–Wallis tests; Spearman correlations with bootstrap confidence intervals; standardized regression adjusted for age, sex, and BMI; robust covariance estimates; principal component analysis (PCA), winsorization, leave-one-domain/marker-out analyses, and missing-BMI sensitivity models. Results: The lower, intermediate, and higher relative melatonergic tertiles included 105, 104, and 105 adults, respectively. The melatonergic-axis score correlated inversely with integrated systemic burden (Spearman ρ = −0.944; 5000-resample bootstrap 95% CI, −0.953 to −0.931; p < 0.001). In age-, sex-, and BMI-adjusted complete-case models (N = 250), each 1 SD higher axis score was associated with a 0.95 SD lower integrated burden (β = −0.949; HC3 95% CI, −0.983 to −0.915; p < 0.001). Results were similar for separate plasma melatonin and aMT6s models, winsorized composites, a PCA-derived score (PC1 explained 75.5% of marker variance; ρ = −0.947), leave-one-domain/marker-out analyses, and missing-BMI sensitivity models. Conclusions: Lower relative melatonergic status was associated with a highly coordinated adverse systemic biomarker pattern. The exceptional magnitude of the association requires audit of primary assay provenance and independent external replication. Because cancer, microbiome, and liquid biopsy endpoints were not measured, oncology implications remain untested prospective hypotheses.
- Open Access
- 30 June 2026
- Published by MDPI AG in Preprints.org
Melatonergic Deficiency, Oxidative Stress, Microbiome Dysbiosis and CTC/cfDNA Progression Markers Across the Cancer Continuum: An Integrative Adult Biomarker Study
Background/Objectives: Melatonin, gut microbiome integrity, oxidative stress and liquid-biopsy biomarkers may represent linked biological layers across tumor initiation, promotion and progression. We aimed to integrate source biomarker data and prior translational materials into a Cancers-oriented research article, using the adult biomarker workbook as the primary statistical dataset. Methods: We performed an adult-only cross-sectional analysis of a deidentified biomarker workbook. Participants younger than 18 years were excluded. Plasma melatonin and 24-hour urinary aMT6s were combined into a melatonergic-axis score and categorized into tertiles. Inflammatory, oxidative-damage, antioxidant-deficit and biological-aging/injury composite z-scores were computed. Associations were assessed using Spearman correlation, Kruskal-Wallis tests and complete-case linear regression adjusted for age, sex and BMI. Previously reported CTC/cfDNA and melatonin-microbiome materials were used only for mechanistic framing. Results: The primary analysis included 314 adults. Low, intermediate and preserved melatonergic tertiles contained 105, 104 and 105 participants, respectively. Lower melatonergic status was associated with higher inflammatory, oxidative-damage, antioxidant-deficit and biological-aging/injury scores (all Kruskal-Wallis p < 0.001). The melatonergic-axis score correlated strongly and inversely with the integrated oncogenic-stress score (Spearman rho = -0.944, p < 0.001). In complete-case adjusted models (N = 250), each 1-SD higher melatonergic-axis score was associated with a 0.95-SD lower integrated oncogenic-stress score (95% CI, -0.98 to -0.92; p < 0.001). Conclusions: Reduced melatonergic status was associated with a coordinated pro-inflammatory, pro-oxidative and accelerated biological-aging phenotype. Prospective oncology studies should test whether this phenotype predicts microbiome dysbiosis, CTC/cfDNA emergence and cancer progression.
- 30 June 2026
- Published by MDPI AG in Preprints.org
Open AccessMelatonergic Deficiency, Oxidative Stress, Microbiome Dysbiosis and CTC/cfDNA Progression Markers Across the Cancer Continuum: An Integrative Adult Biomarker Study
Background/Objectives: Melatonin, gut microbiome integrity, oxidative stress and liquid-biopsy biomarkers may represent linked biological layers across tumor initiation, promotion and progression. We aimed to integrate source biomarker data and prior translational materials into a Cancers-oriented research article, using the adult biomarker workbook as the primary statistical dataset. Methods: We performed an adult-only cross-sectional analysis of a deidentified biomarker workbook. Participants younger than 18 years were excluded. Plasma melatonin and 24-hour urinary aMT6s were combined into a melatonergic-axis score and categorized into tertiles. Inflammatory, oxidative-damage, antioxidant-deficit and biological-aging/injury composite z-scores were computed. Associations were assessed using Spearman correlation, Kruskal-Wallis tests and complete-case linear regression adjusted for age, sex and BMI. Previously reported CTC/cfDNA and melatonin-microbiome materials were used only for mechanistic framing. Results: The primary analysis included 314 adults. Low, intermediate and preserved melatonergic tertiles contained 105, 104 and 105 participants, respectively. Lower melatonergic status was associated with higher inflammatory, oxidative-damage, antioxidant-deficit and biological-aging/injury scores (all Kruskal-Wallis p < 0.001). The melatonergic-axis score correlated strongly and inversely with the integrated oncogenic-stress score (Spearman rho = -0.944, p < 0.001). In complete-case adjusted models (N = 250), each 1-SD higher melatonergic-axis score was associated with a 0.95-SD lower integrated oncogenic-stress score (95% CI, -0.98 to -0.92; p < 0.001). Conclusions: Reduced melatonergic status was associated with a coordinated pro-inflammatory, pro-oxidative and accelerated biological-aging phenotype. Prospective oncology studies should test whether this phenotype predicts microbiome dysbiosis, CTC/cfDNA emergence and cancer progression.
- Open Access
- 29 June 2026
- Published by MDPI AG in Preprints.org
AminoTriComplex in Integrative Oncology: Integrated Preclinical Safety and Prospective Clinical Evidence in Metastatic Solid Tumors
Multi-component nutraceutical platforms are widely used in integrative oncology, yet standardized quality control, safety qualification, and biomarker-linked evidence remain limited. We integrated GMP manufacturing/QC data, GLP/OECD toxicology, an independent exploratory cancer-cell screening study, and prospective clinical evidence for AminoTriComplex across metastatic cancers. The in vitro screen evaluated coded AminoTriComplex (G1; 10 μg/mL for 48 hours) in 14 human cancer and non-tumor cell lines using a sulforhodamine B assay. Clinical datasets included a double-blind randomized placebo-controlled trial in metastatic colorectal cancer (mCRC; n=72; 12 weeks) and controlled studies in stage IV lung adenocarcinoma (n=212; chemotherapy adjunct) and refractory triple-negative breast cancer (TNBC; n=266; metronomic backbone). Endpoints were RECIST v1.1 response, progression-free survival (PFS), CTCAE v5.0 safety, and a translational triad of Survivin, Cystatin C, and MT1/melatonin rhythm restoration. G1 produced the strongest broad viability reduction among four coded samples, although effects in HUVEC and BEAS-2B showed that tumor selectivity was not established. In mCRC, ORR was 53% versus 12% and median PFS 8.7 versus 3.2 months (HR 0.46). In lung adenocarcinoma, ORR was 48.7% versus 33.0% and DCR 78.3% versus 55.7%, without higher grade ≥3 hematologic toxicity. In TNBC, ORR was 46.3% versus 12.6% and median PFS 8.9 versus 3.4 months (HR 0.42), with concordant biomarker and tumor-microenvironment shifts. No signal of added serious clinical toxicity was observed. Final external preclinical safety assessments by Eurofins (Germany) and the Gamaleya National Research Center did not reveal mutagenic, genotoxic, embryotoxic, or carcinogenic potential under the tested conditions, and aged-rat experiments indicated enhanced mismatch-repair/DNA-repair activity. The non-selective single-dose cell-line signal nevertheless requires formal dose-response and selectivity studies. Trial registration: registry information should be inserted prior to submission; the mCRC trial was not prospectively registered.
- 29 June 2026
- Published by MDPI AG in Preprints.org
Open AccessAminoTriComplex in Integrative Oncology: Integrated Preclinical Safety and Prospective Clinical Evidence in Metastatic Solid Tumors
Multi-component nutraceutical platforms are widely used in integrative oncology, yet standardized quality control, safety qualification, and biomarker-linked evidence remain limited. We integrated GMP manufacturing/QC data, GLP/OECD toxicology, an independent exploratory cancer-cell screening study, and prospective clinical evidence for AminoTriComplex across metastatic cancers. The in vitro screen evaluated coded AminoTriComplex (G1; 10 μg/mL for 48 hours) in 14 human cancer and non-tumor cell lines using a sulforhodamine B assay. Clinical datasets included a double-blind randomized placebo-controlled trial in metastatic colorectal cancer (mCRC; n=72; 12 weeks) and controlled studies in stage IV lung adenocarcinoma (n=212; chemotherapy adjunct) and refractory triple-negative breast cancer (TNBC; n=266; metronomic backbone). Endpoints were RECIST v1.1 response, progression-free survival (PFS), CTCAE v5.0 safety, and a translational triad of Survivin, Cystatin C, and MT1/melatonin rhythm restoration. G1 produced the strongest broad viability reduction among four coded samples, although effects in HUVEC and BEAS-2B showed that tumor selectivity was not established. In mCRC, ORR was 53% versus 12% and median PFS 8.7 versus 3.2 months (HR 0.46). In lung adenocarcinoma, ORR was 48.7% versus 33.0% and DCR 78.3% versus 55.7%, without higher grade ≥3 hematologic toxicity. In TNBC, ORR was 46.3% versus 12.6% and median PFS 8.9 versus 3.4 months (HR 0.42), with concordant biomarker and tumor-microenvironment shifts. No signal of added serious clinical toxicity was observed. Final external preclinical safety assessments by Eurofins (Germany) and the Gamaleya National Research Center did not reveal mutagenic, genotoxic, embryotoxic, or carcinogenic potential under the tested conditions, and aged-rat experiments indicated enhanced mismatch-repair/DNA-repair activity. The non-selective single-dose cell-line signal nevertheless requires formal dose-response and selectivity studies. Trial registration: registry information should be inserted prior to submission; the mCRC trial was not prospectively registered.
- Open Access
- 25 June 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (13) , 5753
A Dysbiosis–Urolithin A Depletion–Low 6-Sulfatoxymelatonin Triad as a Composite Biomarker Framework Across Age-Related Vascular and Malignant Disease States
Urolithin A (UA) is a gut microbiota-derived postbiotic generated from dietary ellagitannins, while urinary 6-sulfatoxymelatonin (6-SMT) is a surrogate marker of nocturnal melatonin output. We explored whether dysbiosis, UA depletion, and low 6-SMT define an ordered biomarker pattern across healthy aging, salt-sensitive hypertension, and advanced cancer. In this pilot observational study, patients with advanced solid tumors were classified as Cancer Group 1 (higher aggressiveness; n = 231) or Cancer Group 2 (lower aggressiveness; n = 118) and compared with healthy older controls (n = 117) and elderly participants with salt-sensitive hypertension (n = 333). Plasma UA decreased stepwise from controls (2.24 [1.38–3.12] nmol/L) to salt-sensitive hypertension (1.20 [0.76–1.89] nmol/L), Cancer Group 2 (0.60 [0.32–0.91] nmol/L), and Cancer Group 1, in which most samples were at or below the assay limit (overall p < 0.0001; trend p < 0.0001). Twenty-four-hour urinary 6-SMT declined in parallel, whereas the dysbiosis score, interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), interleukin-8 (IL-8), and malondialdehyde (MDA) increased, and antioxidant indices decreased across the ordered groups (all p < 0.0001). These cross-sectional findings support a hypothesis-generating biomarker framework linking dysbiosis, postbiotic depletion, circadian disruption, inflammation, and redox imbalance across age-related disease states.
- 25 June 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (13) , 5753
Open AccessA Dysbiosis–Urolithin A Depletion–Low 6-Sulfatoxymelatonin Triad as a Composite Biomarker Framework Across Age-Related Vascular and Malignant Disease States
Urolithin A (UA) is a gut microbiota-derived postbiotic generated from dietary ellagitannins, while urinary 6-sulfatoxymelatonin (6-SMT) is a surrogate marker of nocturnal melatonin output. We explored whether dysbiosis, UA depletion, and low 6-SMT define an ordered biomarker pattern across healthy aging, salt-sensitive hypertension, and advanced cancer. In this pilot observational study, patients with advanced solid tumors were classified as Cancer Group 1 (higher aggressiveness; n = 231) or Cancer Group 2 (lower aggressiveness; n = 118) and compared with healthy older controls (n = 117) and elderly participants with salt-sensitive hypertension (n = 333). Plasma UA decreased stepwise from controls (2.24 [1.38–3.12] nmol/L) to salt-sensitive hypertension (1.20 [0.76–1.89] nmol/L), Cancer Group 2 (0.60 [0.32–0.91] nmol/L), and Cancer Group 1, in which most samples were at or below the assay limit (overall p < 0.0001; trend p < 0.0001). Twenty-four-hour urinary 6-SMT declined in parallel, whereas the dysbiosis score, interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), interleukin-8 (IL-8), and malondialdehyde (MDA) increased, and antioxidant indices decreased across the ordered groups (all p < 0.0001). These cross-sectional findings support a hypothesis-generating biomarker framework linking dysbiosis, postbiotic depletion, circadian disruption, inflammation, and redox imbalance across age-related disease states.
- Open Access
- 15 May 2026
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (5) , 515
Nocturnal Melatonin Amplitude Collapse Is Associated with Age-Independent Convergence of Microbiome and Glymphatic Biomarkers
Circadian desynchronization is increasingly linked to metabolic, immune, neurocognitive, and oncological disease, but integrated clinical phenotyping across endocrine, microbiome, metabolic, and neuroimaging domains remains limited. We conducted a prospective, single-centre, observational study in 179 symptomatic patients referred for chronic multisystem features consistent with circadian dysregulation and 107 practically healthy controls. Circadian melatonin status was assessed using fractionated 24 h urinary 6-sulfatoxymelatonin (aMT6s) and standardized dim-light plasma sampling at daytime (14:00–16:00) and nocturnal (02:00–04:00) windows. Microbiome composition was assessed by 16S rRNA sequencing, urolithin A by targeted metabolomics, and putative glymphatic/perivascular clearance by MRI-derived DTI-ALPS index, perivascular space scoring, and white-matter-hyperintensity (WMH) volumetry. Patients showed markedly reduced nocturnal melatonin output and loss of day–night contrast (night aMT6s 10.2 vs. 40.6 ng/mL; urinary aMT6s day/night ratio 0.81 vs. 0.14; plasma nocturnal melatonin 12.7 vs. 54.4 pg/mL; all p < 0.0001), accompanied by altered cortisol day–night patterning. Patients also showed reduced microbiome diversity, depletion of Gordonibacter and Ellagibacter, lower plasma urolithin A, higher WMH volume and perivascular space scores, and a lower DTI-ALPS index. Age distributions broadly overlapped in the individual-level dataset, and key biomarkers were not significantly correlated with chronological age within the patient cohort; however, this finding is interpreted as an exploratory absence of detectable age gradient within the symptomatic cohort, not as proof of biological age-independence. Overall, the data support a coherent cross-sectional association among blunted nocturnal melatonin rhythmicity, dysbiosis/urolithin depletion, and MRI markers compatible with impaired perivascular clearance. The MGM axis framework should be regarded as hypothesis-generating; causal direction, melatonin receptor involvement, and AQP4-related mechanisms require longitudinal and mechanistic validation.
- 15 May 2026
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (5) , 515
Open AccessNocturnal Melatonin Amplitude Collapse Is Associated with Age-Independent Convergence of Microbiome and Glymphatic Biomarkers
Circadian desynchronization is increasingly linked to metabolic, immune, neurocognitive, and oncological disease, but integrated clinical phenotyping across endocrine, microbiome, metabolic, and neuroimaging domains remains limited. We conducted a prospective, single-centre, observational study in 179 symptomatic patients referred for chronic multisystem features consistent with circadian dysregulation and 107 practically healthy controls. Circadian melatonin status was assessed using fractionated 24 h urinary 6-sulfatoxymelatonin (aMT6s) and standardized dim-light plasma sampling at daytime (14:00–16:00) and nocturnal (02:00–04:00) windows. Microbiome composition was assessed by 16S rRNA sequencing, urolithin A by targeted metabolomics, and putative glymphatic/perivascular clearance by MRI-derived DTI-ALPS index, perivascular space scoring, and white-matter-hyperintensity (WMH) volumetry. Patients showed markedly reduced nocturnal melatonin output and loss of day–night contrast (night aMT6s 10.2 vs. 40.6 ng/mL; urinary aMT6s day/night ratio 0.81 vs. 0.14; plasma nocturnal melatonin 12.7 vs. 54.4 pg/mL; all p < 0.0001), accompanied by altered cortisol day–night patterning. Patients also showed reduced microbiome diversity, depletion of Gordonibacter and Ellagibacter, lower plasma urolithin A, higher WMH volume and perivascular space scores, and a lower DTI-ALPS index. Age distributions broadly overlapped in the individual-level dataset, and key biomarkers were not significantly correlated with chronological age within the patient cohort; however, this finding is interpreted as an exploratory absence of detectable age gradient within the symptomatic cohort, not as proof of biological age-independence. Overall, the data support a coherent cross-sectional association among blunted nocturnal melatonin rhythmicity, dysbiosis/urolithin depletion, and MRI markers compatible with impaired perivascular clearance. The MGM axis framework should be regarded as hypothesis-generating; causal direction, melatonin receptor involvement, and AQP4-related mechanisms require longitudinal and mechanistic validation.
- Open Access
- 4 May 2026
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 20 (1)
Exceptional and typical biomarker responses to AminoTriComplex in metastatic prostate cancer: a case series
Metastatic prostate cancer (mPCa) remains a major cause of mortality in men. AminoTriComplex, a multicomponent phytochemical–melatonin formulation, t
- 4 May 2026
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 20 (1)
Open AccessExceptional and typical biomarker responses to AminoTriComplex in metastatic prostate cancer: a case series
Metastatic prostate cancer (mPCa) remains a major cause of mortality in men. AminoTriComplex, a multicomponent phytochemical–melatonin formulation, t
- Open Access
- 22 April 2026
- Published by MDPI AG in Preprints.org
Nocturnal Melatonin Amplitude Collapse Is Associated with Age-Independent Convergence of Microbiome and Glymphatic Biomarkers
Background: Circadian desynchronization is increasingly recognized as a transdiagnostic driver of metabolic, neurodegenerative, immune, and oncological pathology. Melatonin, acting primarily through the G-protein-coupled receptors MT1 (MTNR1A) and MT2 (MTNR1B), is the principal endocrine output of the circadian system and exerts pleiotropic oncostatic, antioxidant, and immunomodulatory effects. Whether disrupted melatonin rhythmicity co-segregates with gut dysbiosis, impaired glymphatic clearance, and multi-system biomarker pathology in a clinically identifiable population has not been systematically examined. Aim: To characterize the integrated microbiome–glymphatic–melatonin (MGM) axis in a clinically phenotyped cohort of patients with chronic multisystem symptoms consistent with circadian dysregulation, and to determine whether the resultant biomarker phenotype is age-independent. Methods: We conducted a prospective observational study in 179 patients meeting pre-specified inclusion criteria for circadian dysregulation and 107 practically healthy controls. Circadian melatonin status was assessed using fractionated 24-hour urinary 6-sulfatoxymelatonin (aMT6s) and plasma melatonin at standardized dim-light time windows (daytime 14:00–16:00; nocturnal 02:00–04:00). Microbiome composition was determined by 16S rRNA (V3–V4) sequencing. Urolithin A was quantified by targeted metabolomics. Brain glymphatic function was approximated using the DTI-ALPS index, perivascular spaces scoring, and WMH volumetry. Systemic markers included BNP, CD4/CD8 ratio, and MoCA score. Results: Patients demonstrated a profound collapse of nocturnal melatonin output (aMT6s 10.2 vs 40.6 ng/mL night; Day/Night ratio 0.81 vs 0.14; p< 0.0001 all), constituting a circadian amplitude inversion pattern. Cortisol rhythmicity showed parallel disruption. Microbiome diversity was markedly reduced (Shannon 2.83 vs 5.07), with depletion of urolithin-producing taxa (Gordonibacter, Ellagibacter) and profoundly reduced plasma urolithin A (2.40 vs 25.20 ng/mL). Brain imaging showed elevated WMH volume (9.99 vs 1.54 mL), enlarged perivascular spaces, and reduced DTI-ALPS index (1.05 vs 1.70). Strikingly, MGM-axis biomarkers showed no significant correlation with chronological age within the patient group (Spearman r: −0.10 to +0.09, all p>0.14), indicating age-independent convergence. Conclusions: Circadian desynchronization is associated with a coherent, age-independent MGM-axis phenotype encompassing melatonin amplitude collapse, gut dysbiosis with urolithin A depletion, and imaging markers of impaired brain clearance. This integrated framework identifies tractable multi-domain biomarkers for circadian screening and motivates targeted resynchronization strategies including MT1/MT2-mediated chronotherapy.
- 22 April 2026
- Published by MDPI AG in Preprints.org
Open AccessNocturnal Melatonin Amplitude Collapse Is Associated with Age-Independent Convergence of Microbiome and Glymphatic Biomarkers
Background: Circadian desynchronization is increasingly recognized as a transdiagnostic driver of metabolic, neurodegenerative, immune, and oncological pathology. Melatonin, acting primarily through the G-protein-coupled receptors MT1 (MTNR1A) and MT2 (MTNR1B), is the principal endocrine output of the circadian system and exerts pleiotropic oncostatic, antioxidant, and immunomodulatory effects. Whether disrupted melatonin rhythmicity co-segregates with gut dysbiosis, impaired glymphatic clearance, and multi-system biomarker pathology in a clinically identifiable population has not been systematically examined. Aim: To characterize the integrated microbiome–glymphatic–melatonin (MGM) axis in a clinically phenotyped cohort of patients with chronic multisystem symptoms consistent with circadian dysregulation, and to determine whether the resultant biomarker phenotype is age-independent. Methods: We conducted a prospective observational study in 179 patients meeting pre-specified inclusion criteria for circadian dysregulation and 107 practically healthy controls. Circadian melatonin status was assessed using fractionated 24-hour urinary 6-sulfatoxymelatonin (aMT6s) and plasma melatonin at standardized dim-light time windows (daytime 14:00–16:00; nocturnal 02:00–04:00). Microbiome composition was determined by 16S rRNA (V3–V4) sequencing. Urolithin A was quantified by targeted metabolomics. Brain glymphatic function was approximated using the DTI-ALPS index, perivascular spaces scoring, and WMH volumetry. Systemic markers included BNP, CD4/CD8 ratio, and MoCA score. Results: Patients demonstrated a profound collapse of nocturnal melatonin output (aMT6s 10.2 vs 40.6 ng/mL night; Day/Night ratio 0.81 vs 0.14; p< 0.0001 all), constituting a circadian amplitude inversion pattern. Cortisol rhythmicity showed parallel disruption. Microbiome diversity was markedly reduced (Shannon 2.83 vs 5.07), with depletion of urolithin-producing taxa (Gordonibacter, Ellagibacter) and profoundly reduced plasma urolithin A (2.40 vs 25.20 ng/mL). Brain imaging showed elevated WMH volume (9.99 vs 1.54 mL), enlarged perivascular spaces, and reduced DTI-ALPS index (1.05 vs 1.70). Strikingly, MGM-axis biomarkers showed no significant correlation with chronological age within the patient group (Spearman r: −0.10 to +0.09, all p>0.14), indicating age-independent convergence. Conclusions: Circadian desynchronization is associated with a coherent, age-independent MGM-axis phenotype encompassing melatonin amplitude collapse, gut dysbiosis with urolithin A depletion, and imaging markers of impaired brain clearance. This integrated framework identifies tractable multi-domain biomarkers for circadian screening and motivates targeted resynchronization strategies including MT1/MT2-mediated chronotherapy.
- Open Access
- 3 February 2026
- Published by MDPI AG in Preprints.org
Cisterna Chyli as an Evolutionary Incubator for Metastasis: Comparative Circulating Tumor Cell Phenotyping Across Cisterna Chyli, Peripheral Lymph and Blood in 614 Participants
Background: Circulating tumor cells (CTCs) are key intermediates of hematogenous metastasis, yet their phenotype is shaped by transit through distinct anatomical niches. The cisterna chyli is the central lymphatic conduit draining lipid-rich intestinal lymph and peripheral lymphatics into the venous system. We investigated whether the cisterna chyli functions as a phenotypic “incubator” for aggressive CTC states. Methods: In a 7-year prospective study, intraoperative samples (7.5 mL each) were collected from the cisterna chyli, peripheral lymph, and peripheral blood of 496 patients with stage III–IV solid tumors (21 tumor types). A control cohort of 118 non-oncological patients undergoing surgery after trauma was sampled with the same protocol. CTCs were enumerated by CellSearch and phenotyped using multi-marker immunocytochemistry for proliferation (Ki-67), invasion/migration (MMP-9, CXCR4), epithelial–mesenchymal transition (EMT), and stemness markers. Cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) were quantified across compartments. Results: In the cancer cohort, cisterna chyli CTC counts were markedly higher than in peripheral blood or peripheral lymph (12–15× enrichment across tumor types). Cisterna chyli CTCs showed increased proliferative and invasive phenotypes (Ki-67 ~2.7×; MMP-9 ~3×; CXCR4 ~5×) and enrichment of EMT and stemness programs (Any EMT+ ~2.3×; Any stemness+ ~3.3×; ≥2 stemness markers ~3.4×). cfDNA and ctDNA levels were comparable across the three compartments. In controls, CTC-like events were detected in 23/118 participants (19.5%) with no enrichment reported between compartments. Conclusions: The cisterna chyli harbors a substantially enriched and biologically aggressive CTC subpopulation, consistent with an “evolutionary incubator” model in which lymphatic transit promotes clonal selection and phenotypic plasticity. These findings support cisterna chyli sampling as a high-yield site for intraoperative liquid biopsy and suggest new regional therapeutic opportunities to target lymph-borne metastatic precursors.
- 3 February 2026
- Published by MDPI AG in Preprints.org
Open AccessCisterna Chyli as an Evolutionary Incubator for Metastasis: Comparative Circulating Tumor Cell Phenotyping Across Cisterna Chyli, Peripheral Lymph and Blood in 614 Participants
Background: Circulating tumor cells (CTCs) are key intermediates of hematogenous metastasis, yet their phenotype is shaped by transit through distinct anatomical niches. The cisterna chyli is the central lymphatic conduit draining lipid-rich intestinal lymph and peripheral lymphatics into the venous system. We investigated whether the cisterna chyli functions as a phenotypic “incubator” for aggressive CTC states. Methods: In a 7-year prospective study, intraoperative samples (7.5 mL each) were collected from the cisterna chyli, peripheral lymph, and peripheral blood of 496 patients with stage III–IV solid tumors (21 tumor types). A control cohort of 118 non-oncological patients undergoing surgery after trauma was sampled with the same protocol. CTCs were enumerated by CellSearch and phenotyped using multi-marker immunocytochemistry for proliferation (Ki-67), invasion/migration (MMP-9, CXCR4), epithelial–mesenchymal transition (EMT), and stemness markers. Cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) were quantified across compartments. Results: In the cancer cohort, cisterna chyli CTC counts were markedly higher than in peripheral blood or peripheral lymph (12–15× enrichment across tumor types). Cisterna chyli CTCs showed increased proliferative and invasive phenotypes (Ki-67 ~2.7×; MMP-9 ~3×; CXCR4 ~5×) and enrichment of EMT and stemness programs (Any EMT+ ~2.3×; Any stemness+ ~3.3×; ≥2 stemness markers ~3.4×). cfDNA and ctDNA levels were comparable across the three compartments. In controls, CTC-like events were detected in 23/118 participants (19.5%) with no enrichment reported between compartments. Conclusions: The cisterna chyli harbors a substantially enriched and biologically aggressive CTC subpopulation, consistent with an “evolutionary incubator” model in which lymphatic transit promotes clonal selection and phenotypic plasticity. These findings support cisterna chyli sampling as a high-yield site for intraoperative liquid biopsy and suggest new regional therapeutic opportunities to target lymph-borne metastatic precursors.
- Open Access
- 29 January 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (3) , 1361
Melatonin Biosynthesis, Receptors, and the Microbiota–Tryptophan–Melatonin Axis: A Shared Dysbiosis Signature Across Cardiac Arrhythmias, Epilepsy, Malignant Proliferation, and Cognitive Trajectories
Melatonin, an indolic neuromodulator with putative oncostatic and proposed anti-inflammatory properties, primarily demonstrated in preclinical models, is produced at extrapineal sites—most notably in the gut. Its canonical actions are mediated by high-affinity GPCRs (MT1/MT2) and by NQO2, a cytosolic enzyme with a melatonin-binding site (historically termed “MT3”). A growing body of work highlights a bidirectional interaction between the gut microbiota and host melatonin. We integrated two lines of work: (i) three clinical cohorts—cardiac arrhythmias (n = 111; 46–75 y), epilepsy (n = 77; 20–59 y), and stage III–IV solid cancers (25–79 y)—profiled with stool 16S rRNA sequencing, SCFA measurements, and circulating melatonin/urinary 6-sulfatoxymelatonin and (ii) an age-spanning cognitive cohort with melatonin phenotyping, microbiome analyses, and exploratory immune/metabolite readouts, including a novel observation of melatonin binding on bacterial membranes. Across all three disease cohorts, we observed moderate-to-severe dysbiosis, with reduced alpha-diversity and shifted beta-structure. The core dysbiosis implicated tryptophan-active taxa (Bacteroides/Clostridiales proteolysis and indolic conversions) and depletion of SCFA-forward commensals (e.g., Faecalibacterium, Blautia, Akkermansia, and several Lactobacillus/Bifidobacterium spp.). Synthesised literature indicates that typical human gut commensals rarely secrete measurable melatonin in vitro; rather, their metabolites (SCFAs, lactate, and tryptophan derivatives) regulate host enterochromaffin serotonin/melatonin production. In arrhythmia models, dysbiosis, bile-acid remodelling, and autonomic/inflammatory tone align with melatonin-sensitive antiarrhythmic effects. Epilepsy exhibits circadian seizure patterns and tryptophan–metabolite signatures, with modest and heterogeneous responses to add-on melatonin. Cancer cohorts show broader dysbiosis consistent with melatonin’s oncostatic actions. In the cognitive cohort, the absence of dysbiosis tracked with preserved learning across ages, and exploratory immunohistochemistry suggested melatonin-binding sites on bacterial membranes in ~15–17% of samples. A unifying microbiota–tryptophan–melatonin axis plausibly integrates circadian, electrophysiologic, and immune–oncologic phenotypes. Practical levers include fiber-rich diets (to drive SCFAs), light hygiene, and time-aware therapy, with indication-specific use of melatonin. Our conclusions regarding microbiota–melatonin crosstalk rely primarily on local paracrine effects within the gut mucosa (where melatonin concentrations are 10–400× plasma levels), whereas systemic chronotherapy conclusions depend on circulating melatonin amplitude and phase. This original research article presents primary data from four prospectively enrolled clinical cohorts (total n = 577).
- 29 January 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (3) , 1361
Open AccessMelatonin Biosynthesis, Receptors, and the Microbiota–Tryptophan–Melatonin Axis: A Shared Dysbiosis Signature Across Cardiac Arrhythmias, Epilepsy, Malignant Proliferation, and Cognitive Trajectories
Melatonin, an indolic neuromodulator with putative oncostatic and proposed anti-inflammatory properties, primarily demonstrated in preclinical models, is produced at extrapineal sites—most notably in the gut. Its canonical actions are mediated by high-affinity GPCRs (MT1/MT2) and by NQO2, a cytosolic enzyme with a melatonin-binding site (historically termed “MT3”). A growing body of work highlights a bidirectional interaction between the gut microbiota and host melatonin. We integrated two lines of work: (i) three clinical cohorts—cardiac arrhythmias (n = 111; 46–75 y), epilepsy (n = 77; 20–59 y), and stage III–IV solid cancers (25–79 y)—profiled with stool 16S rRNA sequencing, SCFA measurements, and circulating melatonin/urinary 6-sulfatoxymelatonin and (ii) an age-spanning cognitive cohort with melatonin phenotyping, microbiome analyses, and exploratory immune/metabolite readouts, including a novel observation of melatonin binding on bacterial membranes. Across all three disease cohorts, we observed moderate-to-severe dysbiosis, with reduced alpha-diversity and shifted beta-structure. The core dysbiosis implicated tryptophan-active taxa (Bacteroides/Clostridiales proteolysis and indolic conversions) and depletion of SCFA-forward commensals (e.g., Faecalibacterium, Blautia, Akkermansia, and several Lactobacillus/Bifidobacterium spp.). Synthesised literature indicates that typical human gut commensals rarely secrete measurable melatonin in vitro; rather, their metabolites (SCFAs, lactate, and tryptophan derivatives) regulate host enterochromaffin serotonin/melatonin production. In arrhythmia models, dysbiosis, bile-acid remodelling, and autonomic/inflammatory tone align with melatonin-sensitive antiarrhythmic effects. Epilepsy exhibits circadian seizure patterns and tryptophan–metabolite signatures, with modest and heterogeneous responses to add-on melatonin. Cancer cohorts show broader dysbiosis consistent with melatonin’s oncostatic actions. In the cognitive cohort, the absence of dysbiosis tracked with preserved learning across ages, and exploratory immunohistochemistry suggested melatonin-binding sites on bacterial membranes in ~15–17% of samples. A unifying microbiota–tryptophan–melatonin axis plausibly integrates circadian, electrophysiologic, and immune–oncologic phenotypes. Practical levers include fiber-rich diets (to drive SCFAs), light hygiene, and time-aware therapy, with indication-specific use of melatonin. Our conclusions regarding microbiota–melatonin crosstalk rely primarily on local paracrine effects within the gut mucosa (where melatonin concentrations are 10–400× plasma levels), whereas systemic chronotherapy conclusions depend on circulating melatonin amplitude and phase. This original research article presents primary data from four prospectively enrolled clinical cohorts (total n = 577).